The double-blinded SELECT cardiovascular outcomes trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular (MACE) events over a period of up to 5 years. Read more about its background, methodology, results, and more.
Trial Rationale
Trial Rationale for the SELECT trial
Trial Design
Trial Design for the SELECT trial
Trial Objectives
Trial Objectives for the SELECT trial
Baseline Characteristics
Baseline Characteristics for the SELECT trial
Featured Insights and Resources
Trial Rationale
Trial Rationale for the SELECT trial
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.